Nonsteroidal MRA as a therapeutic option in patients with T2D and CKD

Media formats available:

Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
ACC.24
Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
- Alexander J. Blood, MD
Management of hyperkalemia in CKD and HFrEF
Management of hyperkalemia in CKD and HFrEF
Kidney Disease
Management of hyperkalemia in CKD and HFrEF
- George L. Bakris, MD
- David Bushinsky, MD
- Lars Lund, MD
A practical look at cardiorenal protection for CKD in T2D: Applying recent data
A practical look at cardiorenal protection for CKD in T2D: Applying recent data
Kidney Disease
A practical look at cardiorenal protection for CKD in T2D: Applying recent data
- Carolyn Lam, MD, PhD
- Maria Luiza Caramori, MD, PhD
- Ana Maria Cebrián-Cuenca, MD, PhD
- Pam R. Taub, MD, FACC, FASPC
Management of patients with CKD and HF complicated by hyperkalemia
Management of patients with CKD and HF complicated by hyperkalemia
Kidney Disease
Management of patients with CKD and HF complicated by hyperkalemia
- Ellie Kelepouris, MD
- Stephen J. Greene, MD

PACE-CME